Argenica Therapeutics Ltd · ASX:AGN
Argenica Therapeutics — Investor Presentation (October 2022)
20 slides from Argenica Therapeutics's investor presentation, October 2022
Slide 1: Investor Presentation
INVESTOR ARGENICA THERAPEUTICS PRESENTATION ASX: AGN OCTOBER 2022 1 www.argenica.com.au
Slide 2: Disclaimer
DISCLAIMER This presentation has been prepared by Argenica Therapeutics Limited and its related entities (the “Company”) and is not an offer document. It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company
Slide 3: Novel Neuroprotective Treatments
NOVEL NEUROPROTECTIVE TREATMENTS Argenica is dedicated to developing life-changing treatments to reduce brain damage following stroke and other types of brain injuries. BREAKTHROUGH POSITIVELY ARGENICA THERAPEUTICS NEUROPROTECTIVE IMPACTING SOLUTIONS TO REDUCE LIVES Protecting brain cell death is cr
Slide 4: Key Company Metrics
KEY COMPANY METRICS $8.9M RECENT R&D REBATE PHASE 1 TRIAL CASH @ BANK1 $1.38M FUNDED ARGENICA THERAPEUTICS 86.9M $41M STRONG SHARES ON ISSUE MARKET CAP2 SHARE PRICE PERFORMANCE SINCE IPO (1) Cash balance as @ 30 June 2022 4 (2) Calculated with closing price on @ 18th October being $0.475 www.argenic
Slide 5: Our Lead Drug Candidate: ARG-007
OUR LEAD DRUG CANDIDATE: ARG-007 ARGENICA THERAPEUTICS 10 YEARS IN PHASE 1 TRIAL ALL IP 100% MULTIPLE DEVELOPMENT, APPROVED & OWNED BY GRANTED PATENTS, 25+ PUBLISHED INITIATED ARGENICA INCLUDING THE PAPERS U.S. 5 www.argenica.com.au
Slide 6: Ischemic Stroke Example: How ARG-007 Works
ISCHEMIC STROKE EXAMPLE HOW ARG-007 WORKS ARGENICA THERAPEUTICS INITIAL INFARCTION SETS OFF A CASCADE OF CELL DEATH THAT WILL CONTINUE SPREADING FROM LOCATION Slows the progression of brain cell death Extends treatment window & provides neuroprotection prior to hospital Improves recovery time and qu
Slide 7: ARG-007 Reduces Brain Tissue Death
ARG-007 REDUCES BRAIN TISSUE DEATH Percentage reduction of brain tissue death after stroke 24 Hours after stroke 28 Days after stroke 100% INDUCED INDUCED 90% STROKE STROKE Reduction in brain cell death 80% can make a significant difference to patients’ ARGENICA THERAPEUTICS 70% outcome. It could me
Slide 8: Why Stroke?
WHY STROKE? ARGENICA THERAPEUTICS ONE IN FOUR ONLY 10% THERE ARE NO people will suffer a will recover almost universally available drugs stroke in their lifetime1 completely, due to the extent that protect brain cells of brain cell damage1 following stroke ARGENICA HAS AN OPPORTUNITY TO BECOME A LEA
Slide 9: Argenica Solves an Urgent Unmet Need
ARGENICA SOLVES AN URGENT UNMET NEED ARG-007 REDUCTION REDUCTION IN ADMINISTERED by first responders in the field IN CELL DEATH RECOVERY TIME to minimise brain cell damage. ARGENICA THERAPEUTICS PATIENT HAS A STROKE PATIENT IN AMBULANCE ARRIVES AT HOSPITAL DIAGNOSE STROKE TYPE TREATMENT PLAN REHAB B
Slide 10: Encouraging Results to Date
ENCOURAGING RESULTS TO DATE 70 PERCENT SAFE TO CAN BE REDUCTION ADMINISTER ADMINISTERED IN BRAIN IN THE FIELD2 WITH CLOT ARGENICA THERAPEUTICS TISSUE DEATH DISSOLVING 28 DAYS AFTER DRUGS4 A STROKE1 NO ADVERSE EFFECTS3 These findings are preliminary in nature. A larger dataset will be required for cl
Slide 11: Phase 1 Objectives
PHASE 1 OBJECTIVES 1. EVALUATE THE SAFETY OF ARG-007 WHEN ADMINISTERED ARGENICA THERAPEUTICS 2. IMPROVE THE UNDERSTANDING OF HOW ARG-007 EFFECTS THE BODY 3. DETERMINE THE IDEAL SAFE DOSAGE 11 4. IDENTIFY ANY POSSIBLE ADVERSE REACTIONS www.argenica.com.au
Slide 12: Our Phase 1 Clinical Trial
OUR PHASE 1 CLINICAL TRIAL PARTICIPANTS LOCATION DURATION DESIGN ARGENICA THERAPEUTICS 4 cohorts, with each cohort Single site study conducted at Estimated 6 months, with Double-blind, randomised receiving a different dose of the Linear Clinical Research preliminary findings expected study where par
Slide 13: Clinical Trial Roadmap for Stroke
CLINICAL TRIAL ROADMAP FOR STROKE Oct Nov Dec Jan Feb March April May June ARGENICA HAS ACHIEVED First patient ALL STRATEGIC PRIORITIES successfully dosed SET OUT AT OUR IPO First cohort completed Secured local and international Second cohort completed ARGENICA THERAPEUTICS manufacturing capabilitie
Slide 14: ARG-007 Is a Versatile Technology Platform
DISCOVERY PRE-CLINICAL PHASE 1 PHASE 2 PHASE 3 STROKE Damage to the brain from interruption of its blood supply ARG-007 SIS IS A VERSATILE Surgically Induced Stroke (SIS) occurs during or after surgery TECHNOLOGY HIE PLATFORM ARGENICA THERAPEUTICS Hypoxic ischemic encephalopathy (HIE) develops durin
Slide 15: Advancing Clinical Studies
ADVANCING CLINICAL STUDIES PHASE 1 SAFETY & DOSAGE DATA CAN POTENTIALLY BE USED TO MOVE DIRECTLY INTO MULTIPLE PHASE 2 STUDIES STROKE HIE TRAUMATIC BRAIN INJURY Preclinical studies have shown Argenica’s Preclinical studies show that ARG-007 Data collected from the Phase 1 ARG-007 provides neuroprote
Slide 16: Positive Term HIE Data
POSITIVE TERM HIE DATA Percentage reduction of brain tissue death after HIE in term animal model Infarct Injury 48 Hours after HIE 86% 60 REDUCTION 50 INDUCED HIE + SALINE ARGENICA THERAPEUTICS 40 Significant Infarct Reduction Volume 30 Significant (mm3) (p=0.05) Reduction (p=0.01) 20 10 0 INJURY +
Slide 17: Credentialled & Experienced Team
CREDENTIALLED & EXPERIENCED TEAM GEOFF POCOCK DR LIZ DALLIMORE NON-EXECUTIVE CHAIRMAN CEO • 20 years’ experience in commercialisation of • Over 20 years' experience in R&D, technology commercialisation emerging technologies and capital markets and management consulting, including at KPMG, EY and PWC
Slide 18: Argenica Therapeutics
Prof. Bruno Meloni Geoffrey Donnan CSO & Research Lead Member - CAC Head of Stroke Laboratory Research at UWA and the Perron Institute. Professor Professor of Neurology at The University of Melbourne and former Director Meloni has over 25 years experience as a research scientist, the last 20 in the
Slide 19: Investment Highlights
INVESTMENT HIGHLIGHTS 25+ PUBLISHED STRONG PHASE 1 PAPERS BALANCE SHEET FULLY FUNDED ARGENICA THERAPEUTICS MULTIPLE NEAR TERM EXCEPTIONAL APPLICATIONS PHASE 1 TRIAL & EXPERIENCED & PIPELINE CATALYSIS TEAM + BOARD 19 www.argenica.com.au
Slide 20: Argenica Therapeutics
ARGENICA THERAPEUTICS For further information please contact: Dr Liz Dallimore CEO & Managing Director E: info@argenica.com.au 20 www.argenica.com.au
Argenica Therapeutics — Investor Presentation (October 2022) on 6ix